(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 21 December 2007 (21.12.2007)

(10) International Publication Number WO 2007/145672 A3

(51) International Patent Classification: A61K 38/40 (2006.01) A61K 38/54 (2006.01) A61K 38/17 (2006.01)

(21) International Application Number:

PCT/US2006/060956

(22) International Filing Date:

16 November 2006 (16.11.2006)

(25) Filing Language: **English**

(26) Publication Language: English

(30) Priority Data:

60/804.060 6 June 2006 (06.06.2006) HS 11/160.167 15 November 2006 (15.11.2006) US

- (71) Applicant (for all designated States except US): Zoltan Laboratories LLC [US/US]; 404 20th Street SW, Austin, MN 55912 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): KISS, Zoltan [HU/US]; 404 20th Street SW, Austin, MN 55912 (US).
- Agents: D'SOUZA, Tanya et al.; 90 South Seventh Street, 2200 Wells Fargo Center, Minneapolis, MN 55402-3901 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 3 April 2008

(54) Title: COMBINATIONS OF HUMAN PROTEINS TO ENHANCE VIABILITY OF STEM CELLS AND PROGENITOR **CELLS**

(57) Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase and other members of the alkaline phosphatase family alone or in combination with human transferrin and, optionally, human α_1 -antitrypsin to enhance the proliferation and survival of adult or embryonic stem cells and stem cell-derived progenitor cells in vitro and in vivo.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US06/60956

A. CLASSIFICATION OF SUBJECT MATTER IPC: A61K 38/40(2006.01),38/17(2006.01),38/54(2006.01)		
USPC: 424/94.1 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/94.1		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Pubmed		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST, STN Easy (placental alkaline phosphatase, trasferrin, antitrypsin, stem cells) C. DOCUMENTS CONSIDERED TO BE RELEVANT		
		Relevant to claim No.
US 2005/0048046 A1 (KISS) 03 March 2005 (03.03	3.2005) see abstract, claim 1.	1-9 and 12-26
US 5,405,772 A (PONTING) 11 April 1995 (11.04.1995) see abstract, claim 1.		1-9 and 12-26
Y QING-BAI SHE et al. Alpha-1-antitrypsin can increase insulin-induced mitogenesis in various fibroblast and epithelial cell lines. FEBS Letters 473 (2000) 33-36, see introduction.		
r documents are listed in the continuation of Box C.	See patent family annex.	ļ
Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the	
	principle or theory underlying the invention	
oplication or patent published on or after the international filing date	considered novel or cannot be considered	
the publication date of another citation or other special reason (as	"Y" document of particular relevance; the cl considered to involve an inventive step with one or more other such documents.	when the document is combined
it referring to an oral disclosure, use, exhibition or other means	obvious to a person skilled in the art	
fate claimed	"&" document member of the same patent family	
Pate of the actual completion of the international search Date of mailing of the international search report		
01 August 2007 (01.08.2007)		
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Authorized officer Maury Addet Telephone No. 571-272-1600		
	A61K 38/40(2006.01),38/17(2006.01),38/54(20	A61K 38/40 (2006.01),38/17 (2006.01),38/54 (2006.01) 424/94.1 International Patent Classification (IPC) or to both national classification and IPC DS SEARCHED commentation searched (classification system followed by classification symbols) 24/94.1 Ion searched other than minimum documentation to the extent that such documents are included in searched other than minimum documentation to the extent that such documents are included in the base consulted during the international search (name of data base and, where practicable, search Easy (placental alkaline phosphatase, trasferrin, antitrypsin, stem cells) UMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages US 2005/0048046 A1 (KISS) 03 March 2005 (03.03.2005) see abstract, claim 1. US 5,405,772 A (PONTING) 11 April 1995 (11.04.1995) see abstract, claim 1. QING-BAI SHE et al. Alpha-1-antitrypsin can increase insulin-induced mitogenesis in various fibroblast and epithelial cell lines. FEBS Letters 473 (2000) 33-36, see introduction. To documents are listed in the continuation of Box C. See patent family annex. See patent family annex. **Comment of particular relevance: the considered novel or cannot be considered in the publication date of another cinsion or other special reason (as only the publication date of another cinsion or other special reason (as only the publication of another cinsion or other special reason (as only the publication of another cinsion or other special reason (as only the publication of another cinsion or other special reason (as only the publication of another cinsion or other special reason (as only the publication of another cinsion or other special reason (as only the publication of accounts of another cinsion or other special reason (as only the publication of accounts of another cinsion or other special reason (as only the publication of accounts of another cinsion or other special reason (as only the publication of accounts of publication of accounts of an